Full CoverageTop-Rated Biotech Surges On A Bullish Win In Cancer
By Allison Gatlin
Top news
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
By Tristan Cesar Manalac
Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher
By Paul Taylor
Exelixis' zanzalintinib hits first of two survival goals in pivotal colorectal cancer study
By Pavan Kamat
All coverage
Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future
By Alaric DeArment
Exelixis Targets $5 Billion In Sales With Promising Data In Key Colorectal Cancer Drug Trial, Stock Soars
By Vandana Singh
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment (NASDAQ:EXEL)
By Terry Chrisomalis
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer (EXEL:NASDAQ)
By Jonathan Block, MPH